A rare case of eptifibatide-induced thrombocytopenia.
Khalil KamarKira MacDougallMira AlsheikhSara ParyloYevgeniy SkaradinskiyPublished in: Journal of community hospital internal medicine perspectives (2021)
Eptifibatide is a glycoprotein (GP) IIb/IIIa receptor antagonist, used for the treatment of acute coronary syndrome with high-risk features or ongoing ischemia. Several case reports have described thrombocytopenia as a rare side effect of eptifibatide administration. The exact mechanism remains unclear but may be due to immune destruction of circulating platelets in the peripheral blood. We present the case of acute-onset severe thrombocytopenia in a 76-year-old female undergoing percutaneous coronary intervention.
Keyphrases
- acute coronary syndrome
- rare case
- percutaneous coronary intervention
- peripheral blood
- drug induced
- antiplatelet therapy
- st segment elevation myocardial infarction
- acute myocardial infarction
- st elevation myocardial infarction
- liver failure
- coronary artery bypass grafting
- coronary artery disease
- high glucose
- diabetic rats
- early onset
- respiratory failure
- case report
- oxidative stress
- atrial fibrillation
- coronary artery bypass
- endothelial cells